Valuation: RELH PHAR

Market Cap 13.29B 141M 123M 114M 106M 200M 204M 1.37B 528M 6.55B 528M 516M 22.76B P/E 2024
19.3x
P/E 2025 99.9x
Enterprise Value 13.21B 140M 122M 113M 105M 198M 203M 1.36B 525M 6.51B 525M 513M 22.62B EV / Sales 2024
4.59x
EV / Sales 2025 29.1x
Free-Float
11.03%
Yield 2024
1.22%
Yield 2025 0.05%
1 week-3.77%
Current month-1.41%
1 month-1.41%
3 months-10.49%
6 months-53.67%
Current year-51.76%
1 week 28.13
Extreme 28.13
30.42
1 month 28.13
Extreme 28.13
34.34
3 years 2.04
Extreme 2.0425
65.26
5 years 0.24
Extreme 0.24456215
65.26
Manager TitleAgeSince
Chief Executive Officer 53 2012-05-25
Director of Finance/CFO - 2024-07-09
Compliance Officer - 2026-06-14
Director TitleAgeSince
Director/Board Member 45 2012-05-22
Chairman 53 -
Director/Board Member 51 2023-08-11
Change 5-day change 1-year change 3-year change Capi.($)
-2.99%-3.77%+109.22%+513.30% 137M
+0.64%+1.99%+11.09%+83.48% 47.38B
+0.79%+3.76%+53.94%+103.77% 35.48B
+0.97%+7.57%-3.21%+43.98% 12.33B
+1.81%+4.72%+14.21%+92.51% 11.65B
-2.10%+0.38%+36.72%+126.29% 8.88B
-1.55%+1.77%+20.70%+42.00% 7.21B
+1.37%+7.16%+55.99%-9.35% 6.91B
+1.49%-1.22%+27.78%+223.65% 6.45B
+9.12%+8.29%-29.64%+5.21% 4.94B
Average +1.39%+3.53%+29.68%+122.49% 15.69B
Weighted average by Cap. +0.89%+3.14%+24.58%+85.98%

Financials

2024 2025
Net sales 765M 8.09M 7.08M 6.54M 6.1M 11.49M 11.75M 78.67M 30.37M 377M 30.37M 29.71M 1.31B 326M 3.45M 3.02M 2.79M 2.6M 4.9M 5.01M 33.53M 12.94M 161M 12.94M 12.66M 558M
Net income 185M 1.96M 1.72M 1.58M 1.48M 2.79M 2.85M 19.07M 7.36M 91.45M 7.36M 7.2M 318M 95.75M 1.01M 887K 819K 764K 1.44M 1.47M 9.85M 3.8M 47.24M 3.8M 3.72M 164M
Net Debt -68.26M -722K -632K -584K -545K -1.03M -1.05M -7.02M -2.71M -33.68M -2.71M -2.65M -117M -79.41M -840K -735K -679K -634K -1.19M -1.22M -8.17M -3.15M -39.18M -3.15M -3.09M -136M
Logo RELH PHAR
Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical products globally and domestically. The Company’s product portfolio consists of tablet and capsules (general) solid oral dosage form and small volume parenteral- liquid injection vial and ampules. The Company’s products include Losartan Potassium Tablets USP 50 mg, Glimepiride Tablets USP 2 mg, Pantoprazole Tablets USP 40 mg, Methocarbamol Tablets USP 500 mg, Omeprazole Capsule IP 20 mg, Amlodipine besylate Tablets USP 5 mg, Ranitidine Tablets USP 150 mg, Ranitidine Tablets USP 300 mg, Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Atorvastatin Tablets USP 10mg, Sildenafil citrate Tablets BP 100 mg, Diclofenac Sodium Tablets BP 50 mg, Mebendazole Tablets USP 100 mg, Paracetamol Tablets BP 500 mg, Artemether 80 mg and Lumefantrine 480 mg Tablets, Clotrimazole Vaginal Tablets 100 mg and others.
Employees
-
Date Price Change Volume
26-06-29 28.58 -2.99% 112,404
26-06-25 ₹29.46 +0.44% 208,706
26-06-24 ₹29.33 +0.45% 111,369
26-06-23 ₹29.20 -1.68% 123,500
26-06-22 ₹29.70 -1.82% 230,823